

F. No. ND/MA/21/000064
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

Tele No.011-23236965
Fax.No.011-23236973

To

M/s Ajanta Pharma Limited
Plot no. 43 AB & 44 BCD,
Govt. Industrial Estate, Charkop
Kandivali (W), Mumbai -400067

FDA Bhawan, Kotla Road,
New Delhi-110002

Dated: **18 MAY 2021**

Subject:- A Prospective, Randomized, Parallel, Multicenteric, Phase-III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Molnupiravir in Moderate COVID-19 patients". (Protocol No.: APL/CT/21/05, Ver. 02 (Part II), Dated 12.05.2021)"- reg.

Sir,

With reference to your application dated 10.05.2021, please find enclosed herewith the permission in **Form CT-06, No. CT/ND/ 48/2021** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019 granted based on evaluation in consultation with subject Expert Committee (SEC) as part of accelerated approval process in light of Covid-19 outbreak.

This permission is subject to the conditions, as mentioned below.

Yours faithfully



(Dr. V. G. Somani)
Central Licensing Authority

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
Government of India
New Delhi-110002

Condition of permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7;

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;

- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.
- (xix) CMC data as per the requirement like characterization details, certificate of analysis, stability data etc. should be submitted to CDSCO for initiation of clinical trial.
- (xx) The study should be conducted in two parts and termed as Phase II/III Clinical trial.
- a) In part I, the study should be conducted in 100 patients and submit interim Clinical trial data to CDSCO for further consideration.
- b) RTPCR test should be done at 5, 10 and 15 days of the study.
- c) Sample size should be atleast 1282 moderate COVID patients in randomized 1:1 ratio into Test: Reference arm.
- Test Arm
Molnupiravir 800 mg (4 capsules of 200 mg) administered orally every 12 hours for 5 days (10 doses total) plus Standard of Care.
- Reference Arm
Standard of Care
- d) Patients age limit should be 18 to 60 years.

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

Number of the permission and date of issue CT/ND/48/2021 dated 18 MAY 2021
The Central Licensing Authority hereby permits M/s Ajanta Pharma Limited Plot no. 43
AB & 44 BCD, Govt. Industrial Estate, Charkop, Kandivali (W), Mumbai – 400067,
India to conduct clinical trial of the new drug as per Protocol No.: APL/CT/21/05, Ver.
02(Part II), Dated 12.05.2021 in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial sites: -

Names of the new drug or investigational new drug:	Molnupiravir Capsules 200 mg
Therapeutic class:	Antiviral
Dosage form:	Capsule
Composition:	Each capsule Contains Molnupiravir 200 mg
Indications	For the treatment of moderate COVID - 19 patients

Details of clinical trial site		
Sr. No.	Name of Investigator & Trial Sites	Name of Ethics Committee and address with Ethics Committee registration No
01	Dr. Dnyaneshwar Halnor Vijay Vallabh Hospital and Medical Research Centre, Virar	Vijay Vallabh Hosital, Virar ECR/880/Inst/MH/2017/RR-20
02	Dr. Akash Khobragade St. George's Hospital, Mumbai	Institutional Ethics Committee, Department of Pharmacology, Grant Government Medical College and Sir J J Group of Hospital, Byculla, Mumbai-400008 ECR/382/Inst/MH/2013/RR-19
03	Dr. Dharmendra Jain Banaras Hindu University	Ethics Committee, Banaras Hindu University ECR/1501/Inst/UP/2021
04	Dr. Manish Kumar Jain Maharaja Agrasen Super speciality Hospital, Jaipur	Ethics Committee, Maharaja Agrasen Super speciality Hospital, Jaipur ECR/1222/Inst/RJ/2019
05	Dr. Veerbahadur Singh JLN Medical College, Ajmer	Institutional Ethics Committee, Jawahar Lal Nehru Medical College, Kala Bagh, Ajmer-305001 ECR/1156/Inst/RJ/2018
06	Dr. Y. G. Sundara Raju King george Visakhapatnam, Pradesh	Institutional Ethics Committee King George Hospital, Maharanipeta, Visakhapatnam-530002 ECR/197/Inst/KGH/2013

07	Dr. Giri Raja Rajalakshmi Bangalore	Hospital,	Ethics Committee, Bangalore ECR/1086/Inst/TN/2018	Hospital,
08	Dr. Kaushik Basu Medical College & Kolkata.	Hospital,	Ethics Committee, Medical College & Hospi't Kolkata. ECR/287/Inst/WB/2013/RR-19	
09	Dr. Swapnav Borthakur Dawn Town Guwahati-781006	Hospital,	Ethics Committee Down Town Hospital, Dispur, G S Road, Guwahati-781006 ECR/549/Inst/AS/2014	

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

A/V. G.

(Dr. V. G. Somani)
Central Licensing Authority

Dr. V. G. SOMANI Stamp
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

New Delhi
Date: **18 MAY 2021**